Limitations of a contemporary prostate biopsy: the blind march forward
- PMID: 20816614
- PMCID: PMC2936919
- DOI: 10.1016/j.urolonc.2009.12.022
Limitations of a contemporary prostate biopsy: the blind march forward
Abstract
In an attempt to reduce morbidity, focal targeted therapies and active surveillance have become increasingly popular treatment choices for localized prostate cancer. However, these modalities rely heavily on accurate and reliable tumor localization information provided by a prostate biopsy. Evidence that our contemporary biopsy techniques can do little more than detect some prostate cancers is notably lacking. What is meant by the accuracy and reliability of a prostate biopsy and why they are such important concepts to focal therapy and active surveillance are discussed.
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
References
-
- Siu W, Dunn RL, Shah RB, Wei JT. Use of extended pattern technique for initial prostate biopsy. Journal of Urology. 2005;174(2):505–509. - PubMed
-
- Wikipedia. Accuracy and Precision. 2009
-
- Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. [see comment] New England Journal of Medicine. 358(12):1250–1261. - PubMed
-
- Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer.[see comment]. [Review] [93 refs] Journal of Urology. 1993;180(5):1993–2004. - PubMed
-
- Murat FJ, Gelet A. Current status of high-intensity focused ultrasound for prostate cancer: technology, clinical outcomes, and future. [Review] [43 refs] Current Urology Reports. 2008;9(2):113–121. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical